BioSpace News Archive

DiscGenics, Inc. announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics is presenting at Biotech Showcase 2024.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced preliminary unaudited fourth quarter and full-year 2023 revenue.

Mettler-Toledo International Inc. announced that sales and Adjusted EPS for the fourth quarter of 2023 will be below its previously-issued guidance due to unexpected shipping delays with a new external European logistics service provider, which the Company expects to largely recover in the first quarter of 2024.

The Danish, pharmaceutical company ALK, announced it has successfully completed its acquisition of the business assets of AllerQuest, a U.S.-based company dedicated to manufacturing PRE-PEN® Skin Antigen Test.

Immunexpress, Pty Ltd. announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®.

Jiangsu Vcare PharmaTech Co., Ltd. successfully submitted a New Drug Application to the U.S. Food and Drug Administration for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiovascular and cerebrovascular diseases, including acute coronary syndrome, ischaemic stroke, and peripheral arterial disease.

FogPharma today announced that Mathai Mammen, M.D., Ph.D., chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:30 p.m.

Rallybio Corporation provided an update on recent accomplishments and announced expected 2024 milestones.

ATCC today announced a five-year, $87 million award from the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of next-generation medical countermeasures (MCMs) to protect Americans from public health security threats such as coronaviruses.

Spruce Biosciences, Inc. today provided an update on its clinical programs, upcoming milestones and strategic priorities for advancing tildacerfont for the treatment of adult and pediatric classic congenital adrenal hyperplasia (CAH).